Contineum Therapeutics (CTNM) EBITDA Margin (2023)

Contineum Therapeutics' (CTNM) quarterly EBITDA Margin came in at 77.87% in Q2 2023.

Contineum Therapeutics (CTNM) EBITDA Margin (2023) Analysis & Trends

Contineum Therapeutics' EBITDA Margin history runs 1 years deep, the most recent figure standing at 77.87% for Q2 2023.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 77.87% in Q2 2023; TTM through Jun 2024 was 77.24%, a N/A change from a year earlier, with the FY2023 full-year figure at 32.15%, changed N/A from the prior year.
EBITDA Margin held at 77.87% in Q2 2023 per CTNM's latest filing.
Across five years, EBITDA Margin topped out at 77.87% in Q2 2023 and bottomed at 77.87% in Q2 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Contineum Therapeutics	536.56 Mn	536.56 Mn	-	-

Historic Data

Download Data

Date	Value
Jun 30, 2023	77.87%